77j: Hype?Totally disagree.The co is looking to around $600,000,000 worth of condom sales in the next few yearsUpon which they will be receiving substantial recurring revenues in the form of royalties.The pain gel markets are even greaterThe erectogenic gel,could address a market worth hundreds of millions of dollars,if not more.New product development will bring new markets to fum.I see £10 to £20 share price in the next five years.Gla.
That's a great question. No reason to believe of course that the initial royalty agreement/payment hasn't been triggered yet, but you would think such a significant statement/event would have to be in there.
I am looking for evidence of income from Royalties and Agreements in the March 23rd 2017 Prelim. results.
Below is an extract from the FUM Interim Results published 13.09.2016.
Bottom of Page 3 -
"Commercial manufacture of product for the launch of CSD500 in the first Middle East country, where regulatory approval has already been granted, has already taken place with the launch expected later this year. The initial royalty payment has already been received for this and will be recognised upon launch. We anticipate further launches of the product in other territories during 2017."
CSD500 recently launched in Saudi-Arabia, so I am assuming the royalty payments will be visible in the accounts. Hopefully there will be info about amount of initial sales.
1) It will show the market FUM has a royalties income stream for the first time.
2) It might prompt the business press to articulate more often on FUM progress, and help to stabilise /improve the share price.
I wrote to FUM this morning asking why there is not much product launch or promotions of CSD 500 condoms though they have 8 licenses covering almost everywhere, within an hour James Barder replied me:
"In respect of your concerns over other CSD500 launches. We are actively working on all these launches however in a number of instances, for example China and South Korea, this still requires regulatory approval. In EU territories launch plans are progressing and we will update shareholders as soon as we can however there are considerable commercial sensitivities here and our partners understandably do not want us to flag their intentions to potential competitors ahead of launch. Regards James Barder CEO Futura Medical plc
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.